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Abstract: Charcot–Marie–Tooth (CMT) disease is the most common inherited neuropathy 
and one of the most common inherited diseases in humans. The diagnosis of CMT is tradition-
ally made by the neurologic specialist, yet the optimal management of CMT patients includes 
genetic counselors, physical and occupational therapists, physiatrists, orthotists, mental health 
providers, and community resources. Rapidly developing genetic discoveries and novel gene 
discovery techniques continue to add a growing number of genetic subtypes of CMT. The first 
large clinical natural history and therapeutic trials have added to our knowledge of each CMT 
subtype and revealed how CMT impacts patient quality of life. In this review, we discuss several 
important trends in CMT research factors that will require a collaborative multidisciplinary 
approach. These include the development of large multicenter patient registries, standardized 
clinical instruments to assess disease progression and disability, and increasing recognition and 
use of patient-reported outcome measures. These developments will continue to guide strategies 
in long-term multidisciplinary efforts to maintain quality of life and preserve functionality in 
CMT patients.
Keywords: rehabilitation, genetic diagnosis, patient quality of life, inherited neuropathies, 
hereditary motor and sensory neuropathies, longitudinal care
Introduction
Charcot–Marie–Tooth (CMT) disease is the most common inherited neuropathy, and 
with an estimated prevalence of one in 2,500, one of the most common inherited 
diseases in humans. CMT is a disorder that most commonly causes progressive dis-
tal to proximal weakness and associated atrophy as well as sensory deficits, usually 
affecting the feet and legs at onset. It progresses in a length-dependent fashion even-
tually affecting the hands, but its clinical phenotype can range from mild functional 
limitations to severe complicated diseases. It is broadly classified as demyelinating or 
an axonal form, though intermediate forms exist, each with specific histopathologic, 
electrodiagnostic, and genetic features. While neurologic examination, electrodiag-
nostic techniques, and genetic testing yield diagnostic and prognostic information, a 
multidisciplinary supportive care team is critical to improve the quality of life (QoL) 
in patients for this still incurable disease.
Classification, epidemiology, and genetics
CMT classically refers to inherited motor and sensory neuropathies with a wide 
range of genotypes and phenotypes. Classification of the various types of CMT was 
originally described by Dyck et al in 1975 and employed the term “hereditary motor 
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and sensory neuropathy types I–VII”, also referred to CMT 
types 1–7.1,2 These distinctions rely on electrodiagnostic 
findings of either nerve conduction slowing, representing 
demyelinating disease, or decreased compound muscle 
action potential (CMAP) amplitudes, representing axonal 
injury, as well as the presence of other clinical features. 
This classif ication system described other hereditary 
sensory and sensory-autonomic neuropathies, but did 
not include other primary inherited neuropathies such as 
hereditary neuropathy with pressure palsy and giant axonal 
neuropathy.
While this classification system has provided a useful 
basis to better understand clinical, pathological, and elec-
trodiagnostic phenotype variability, identification of genetic 
etiologies has furthered our understanding of the pathogen-
esis of CMT and allowed for further clinical refinement. The 
most commonly encountered forms of CMT are generally 
classified as type 1 (demyelinating) and type 2 (axonal). 
Occasional cases share features of both axonal and demy-
elinating forms with intermediate conduction velocities, 
and have been recently reviewed by Nicholson and Myers.3 
For each CMT subtype, the known genetic classification is 
denoted as a letter to identify the genetic etiology. An over-
view of single gene causes of CMT based on inheritance 
patterns, pathology, and genetics had been simplified and 
described by Bird and is summarized in Table 1.4 It should be 
noted that there are rare allelic and complex CMT disorders; 
for instance, mutations in MFN2 that cause CMT2A and rare 
forms such as CMT6.5,6
The prevalence of CMT has been estimated as one in 
2,500, but depending on geographic populations studied, 
this estimate has ranged from one in ∼1,200 to 9,200.7–10 
With respect to the subtypes of CMT, CMT type 1 is 
thought most common, representing approximately half 
to 80% of all CMT.11–14 In certain populations (Japan) or 
when sporadic cases are included, a higher prevalence of 
CMT2 is observed. Intermediate forms, which share fea-
tures of types 1 and 2, consistently make up ,4% of cases. 
In CMT type 1, PMP22 duplication (CMT1A) make up 
the vast majority, with North American studies in clinical 
populations consistently showing that PMP22 duplication 
and point mutations account for ∼50% or more of CMT1; 
international studies are variable and report ranges from 
13% to 67%. The remaining genes known to cause CMT1 
(LITAF, EGR2, and NEFL) likely account for ∼10% or less 
of CMT1. In CMT type 2, mutations in MFN2 (CMT2A) 
are thought to account for 15%–20% of CMT2 in clinical 
studies, with other CMT2 genes (Rab7, TRPV4, GARS, 
NEFL, HSPB1, GDAP, HSPB8) accounting for a very small 
minority of cases.6,15–17
Clinical diagnosis
The classic CMT patient will usually present with complaints 
of lower extremity weakness, foot drop, and foot deformity 
which is familial. Examination reveals sensory deficits and 
motor weakness distally with associated muscular atrophy 
and absent deep tendon reflexes. If there is a family history 
of similar symptoms or diagnosis of neuropathy, CMT is a 
likely diagnosis if no other neurologic signs or symptoms 
are revealed. In cases without a clear family history, other 
neurologic diagnosis within the family should be explored, 
as family members may have been incorrectly diagnosed. 
In both sporadic and hereditary cases, reversible causes of 
neuropathy should be ruled out, and nerve conduction studies 
should be performed to confirm the diagnosis, distinguish 
from other neurologic entities, and further classify the CMT 
type. In rare cases, CMT may present with other neurologic 
symptoms, such as optic atrophy, ataxia, and spasticity. Care-
ful evaluation and consideration is recommended for rare 
CMT subtypes or alternative neurologic diagnoses. More 
detailed discussion of clinical diagnosis can be found in 
several recent publications focusing on this topic.18,19
Genetic diagnosis and counseling
With electrodiagnostic confirmation and classification of 
CMT, the decision to pursue genetic testing depends on many 
factors. A genetic counselor is an invaluable member of the 
multidisciplinary team and can be essential in helping the 
patient navigate the ethical, financial, and technical aspects 
of genetic testing. Certainly for women in their reproductive 
years, the confirmation of a heritable disease can have an 
impact on reproductive decisions. Likewise, an asymptom-
atic but concerned member of a known affected family may 
have an interest in genetic testing. However, beyond genetic 
confirmation of the diagnosis, the results of genetic testing do 
not currently influence subsequent treatment or management 
of CMT. Even with the decreasing cost of commercial testing, 
it still remains expensive and the patient may encounter prob-
lems with insurance coverage for testing. Beyond testing the 
most common genes, there are diminishing returns in testing 
the increasing number of rare genes unless a specific sign, 
symptom, or inheritance pattern allows for a more specific 
approach. In a large study of ∼18,000 individuals referred 
to commercial testing for CMT, mutations were identified 
in ∼18%, leaving the large majority without a clear genetic 
etiology.12 Of the patients with identified mutations, 94.9% 
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had mutations in PMP22, MPZ, MFN2, or GJB1. These 
numbers are not in agreement with previous studies which 
report ∼60% diagnostic rate with genetic testing in confirmed 
CMT populations, likely reflecting differences in selection 
of patients for genetic testing between CMT/neuromuscular 
specialists and non specialists.20
The advent of next-generation sequencing which can look 
for mutations in CMT gene panels, whole exome or genome, 
can circumvent complex and potentially costly algorithmic 
approaches with parallel sequencing panels of CMT genes, 
the whole exome, or even whole genome.12,21 However, the 
problem of identifying disease-causing variants not previously 
Table 1 Overview of CMT clinical type and genetic subtypes
Type Pathology/phenotype Inheritance % of CMT Subtype and gene
CMT1 –  Myelin abnormalities
–  Distal weakness, atrophy,  
and sensory loss
–  Onset: ∼5–∼20 years
–  Motor NCv ,38 m/s
AD 50–80 CMT1A PMP22
CMT1B MPZ
CMT1C LITAF
CMT1D EGR2
CMT1e PMP22
CMT1F/2e NEFL
CMT2 –  Axonal degeneration
–  Distal weakness and atrophy,  
variable sensory involvement
–  Complicated and severe  
cases described
–  Motor NCv .38 m/s
–  Onset: variable
AD 10–15 CMT2A MFN2
CMT2B RAB7A
CMT2C TRPV4
CMT2D GARS 
CMT2e/1F NEFL 
CMT2F HSPB1 
CMT2G 12q12-q13
CMT2H/2K GDAP1
CMT2i/2J MPZ
CMT2L HSPB8
CMT2N AARS
CMT2M DMN
CMT2O DYNC1H1
CMT2P LRSAM1
CMT2S IGHMBP2
CMT2T DNAJB2
CMT2U MARS
intermediate  
form
–  Myelinopathy and axonal
–  Motor NCv .25 m/s and  
,38 m/s
AD ,4 Di-CMTA Unknown
Di-CMTB DNM2 
Di-CMTC YARS 
Di-CMTD MPZ
Di-CMTF GNB4
CMT4 –  Demyelinating
–  Recessive
–  variable presentations/ 
phenotypes
AR Rare CMT4A GDAP1
CMT4B1 MTMR2
CMT4B2 SBF2
CMT4B3 SBF1
CMT4C SH3TC2
CMT4D NDRG1
CMT4e EGR2
CMT4F PRX
CMT4G HK1
CMT4H FGD4
CMT4J FiG4
CMT2B1 LMNA
CMT2B2 MED25
CMTX –  Axonal degeneration with  
myelin abnormalities
XL 10–15 CMTX1 GJB1
CMTX2 Xp22.2
CMTX3 Unknown
CMTX4 AIFM1
CMTX5 PRPS1
CMTX6 PDK3
Abbreviations: CMT, Charcot–Marie–Tooth; NCv, nerve conduction velocity; AR, autosomal recessive; AD, autosomal dominant; XL, X-linked. 
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described in the literature over variants of unknown signifi-
cance is a significant barrier not unique to CMT. Sequence 
databases, such as the NHLBI Exome Sequencing Project 
Exome Variant Server (http://evs.gs.washington.edu/EVS/), 
can be a helpful aid in discerning common polymorphisms 
from rare putative disease-causing variants. An invaluable 
resource for referencing disease-causing variants is the 
Mutation Database of Inherited Peripheral Neuropathies 
(IPNMDB) curated by Vincet Timmerman at the University 
of Antwerp (http://www.molgen.ua.ac.be/CMTMutations/
Home/Default.cfm). Beyond its evolving commercial appli-
cation in identifying known disease-causing mutations, whole 
exome and whole genome sequencing remains an important 
research tool in the search for new CMT genes, adding to a list 
of over 870 mutations across more than 80 genes. However, a 
cost conscious sequential approach should be taken by the 
clinician, as four genes (PMP22 duplication, GJB1, MPZ, 
MFN2) represent .90% of familial CMT cases. A focused 
CMT gene panel would reasonably precede whole exome 
or genome sequencing in order to optimize costs, time, and 
chances of diagnostic genetic achievement.
With such a complicated clinical and genetic hetero-
geneity, genetic counseling is an essential component of 
multidisciplinary care for the CMT patient. Many times, 
the genetic counselor directly deals with the emotional and 
psychosocial consequences of the loss of independence, 
emotional pain, embarrassment, stress around reproduction, 
the impact of wearing orthopedic devices, and anxiety over 
imminent progressive disability.22 A recent review of genetic 
counseling in CMT described the benefits of genetic testing 
as: 1) establishing the diagnosis and subtype; 2) confirming 
inheritance pattern which may be important in reproductive 
counseling; 3) allow for option of prenatal or pre implantation 
diagnosis and targeted testing of other family members; 4) 
allows for participation in natural history studies and clini-
cal trials which are genotype or CMT subtype focused; 5) 
allows for more refined prognostication based on the pub-
lished literature about the specific mutation; and 6) allows 
for diagnosed patients to connect with members of the CMT 
community with the same diagnosis.23 The same review 
suggested that a standard genetic counseling meeting with 
CMT patients should optimally address the aforementioned 
items as well as providing support group information or other 
community resources, assessment of need for work and home 
support service, determination of workplace and insurance 
compliance with Americans with Disabilities Act and Genetic 
Information Nondiscrimination Act of 2008, assessment of 
the psychosocial impact of diagnosis, discussion of possible 
delays and misdiagnosis prior to confirmed CMT diagnosis, 
short discussion of symptomatic treatments and encourage-
ment to participate in CMT research studies.
Natural history
CMT is a progressive disease with a wide range of age of 
onset and severity. The classically described clinical presen-
tation developed prior to knowledge of its genetic heterogene-
ity and given our current understanding of genetic prevalence, 
likely best describes CMT1. Indeed, the only CMT types with 
natural history data are CMT1A and CMTX. The natural 
history of CMT2 or more rare CMT subtypes has yet to be 
described. What follows is a description of CMT treated as 
a generalized disease entity.
Both demyelinating and axonal forms of CMT are 
thought of as a length-dependent disease process, which 
first affects the distal lower extremities. Its progression is 
usually steady and slow, except when a known triggering 
or exacerbating factors such as chemotherapy, trauma, or 
other stressor such as surgery can precipitate symptoms in 
the asymptomatic patient or cause a temporary acceleration 
of progression.
Symmetric strength deficits are hallmark features and 
are typically seen mostly distal to the knee, but also in the 
wrist and hand as the disease progresses into later stages. 
Mild-to-moderate proximal musculature weakness and 
tremors may also develop in later stages of CMT. Pes cavus, 
equinovarus, hammertoes, and claw-hand deformities are 
often prevalent in many patients with CMT.24 On exami-
nation, loss of light touch, proprioception, vibration, hot/
cold, and pain may be present at diagnosis and with disease 
progression. Most patients with CMT do not initially com-
plain of any loss of sensation; however, it is often present 
on physical examination. There can be varying degrees of 
sensory involvement, but by the time sensory symptoms 
reach the knee, they often begin in the hands in a classic 
stocking–glove distribution.
Weakness in the anterior lower leg muscles of dorsi-
flexion may frequently lead to “foot drop” and can have a 
strong impact on ambulation and function, and more affected 
patients could eventually progress to a non-ambulatory 
status confined to a wheelchair.25–27 Subsequent weakness 
in the peroneal muscles of eversion in the lower leg could 
also allow for excessive inversion and instability at the ankle 
joint, making the patient particularly vulnerable to sprains 
and falls.28 Also notable, weakness in ankle dorsiflexors may 
lead to subsequent tightening of the gastrocnemius, soleus, 
and fibrotic changes in the heel cord Achilles tendon, and may 
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put the patient at risk for developing an ankle contracture.25,28 
Very late-stage or severe impairments may cause contraction 
of the unopposed antagonist muscles of the legs, and even 
in the hands.25,27
Electrodiagnostic features
As mentioned earlier, classification of CMT is based on 
electrodiagnostic findings of either nerve conduction slow-
ing (,38 m/s) in demyelinating forms, or decreased CMAP 
amplitudes with preserved conduction speeds in axonal 
forms. Occasionally, nerve conduction slowing may fall 
into intermediate range between 25 m/s and 45 m/s and is 
coined intermediate CMT. Studies of demyelinating CMT 
(CMT1A) have shown that while demyelination and slowing 
of nerve conduction velocities appear to be the initial patho-
logical insult, secondary axonal loss as measured by CMAP 
amplitudes and motor unit number estimation (MUNE) 
correlated better with patients’ progressive weakness than 
changes in nerve conduction velocity (NCV).29–32 In children 
with CMT, electrophysiological changes can be detected as 
early as 2 years of age, with abnormally small CMAPs and 
progressively worsening NCV until approximately 6 years 
of age when it stabilizes.33 Similar loss of axons has been 
observed in CMT2, with more proximal involvement and 
without changes in NCV.29 In a study, it appears that at least 
in CMT1A, the largest amount of axonal loss occurs early 
in the disease, with rates of axonal loss when approaching 
age-matched controls, but with a lower underlying reserve.30 
A 5-year longitudinal study of the natural history of CMT1A 
revealed that over 5 years, electrodiagnostic evidence of the 
rate of axonal injury and changes in measured grip strength 
by dynamometry were not different from age-matched con-
trols, but perceived levels of disability were significantly 
worse.34 It has been suggested that progressive disability 
stems from worsening muscle weakness and secondary skel-
etal deformities.30,34 The results of two Italian natural history 
studies in CMT1A and CMT2 describe decreases in distal 
muscle strength and worsening sensation, but no difference 
in QoL, depression, or disability over a 2-year period.35,36
QoL
While CMT patients consistently score lower than healthy 
subjects in QoL measures, there is not a direct longitudinal 
relation between QoL and physical function or disability.37 
The observed paradox between progressive disability and 
preserved QoL measured with instruments such as the Short 
Form-36 has been discussed, and former methods for assess-
ing both disability and QoL may not be optimal for detecting 
pertinent patient-based outcomes.38 There has been an attempt 
to infer disease impact and QoL from clinical examination 
findings. Initial studies suggested that tactile sensory tests 
related to emotional component of QoL, ability to walk on 
toes and heel related to disability and bodily pain.39 Upper 
extremity weakness was the most sensitive marker of over-
all disability as lower extremity strength is impaired in all 
CMT patients and likely reaching a ceiling effect early in the 
disease. A study has demonstrated lower leg weakness and 
cramping correlated with low QoL.40 This same study found 
worse physical functioning scores as compared to patients 
with epilepsy, diabetes mellitus, angina, and stroke patients 
suggesting that the impact of CMT on QoL had previously 
been underestimated.
There have been descriptions of the natural history of 
CMT1 and CMTX, but prior to the last decade, the relative 
rareness of CMT did not allow individual centers to follow 
enough patients to sufficiently power rigorous observational 
studies (particularly of more rare subtypes) or entertain the 
notion of therapeutic trials. Furthermore, there was a lack 
of highly developed disease-specific clinical instruments to 
describe and quantify disease severity. Over the past decade, 
several important developments have co evolved with the 
emergence of CMT therapeutic trials that address these 
shortcomings. The Inherited Neuropathies Consortium (INC; 
https://www.rarediseasesnetwork.org/INC/), part of the Rare 
Diseases Clinical Research Network includes ∼17 multina-
tional sites that collect clinical, electrodiagnostic, and genetic 
data from CMT patients. The INC will play a pivotal role in 
registering CMT patients in sufficient numbers to begin to 
power observational studies across multiple clinical sites.
Another key development is an evolving armament 
of clinical instruments designed to standardize outcome 
measures required for observational studies and therapeutic 
trials. The CMT neuropathy score (CMTNS) is a 36-point 
composite score that rates the patient’s symptoms, signs, and 
neurophysiology, and has been validated as a reproducible 
measure of disability in both axonal and demyelinating forms 
of CMT.41–43 It was designed to improve standardization of 
longitudinal, therapeutic, and multicenter studies. There 
were some initial criticisms that the original CMTNS failed 
to have translatable value in rehabilitation, and lacked sensi-
tivity related to gross motor and sensory scoring.44–46 Many 
of these opinions and observed floor and ceiling effects that 
limited the responsiveness of scores to meaningful clini-
cal changes over time were addressed and modified in the 
CMTNS version 2.45 The CMTNS version 2 is used to classify 
CMT patients into mild (,10, usually walk normally with 
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occasional tripping), moderate (11–20, usually walk indepen-
dently but require ankle–foot orthotic), or severe (.20, usu-
ally require walker or wheelchair) disease. It has been used as 
primary endpoints in therapeutic trials, and in natural history 
studies as discussed in the “Physical therapy and orthoses” 
section.13,16,20,34,47–51 The CMT examination score can be used 
in patients without electrodiagnostic data, and is simply 
the sum of non-neurophysiologic data on the CMTNS.41 
The CMT pediatric examination score is another physi-
cian determined age-adjusted functional assessment score 
designed to assess disability in children.43,52 Many other 
outcome measures of impairment and disability have been 
implemented and studied in CMT – some as secondary 
outcome measures in trials. A thorough cataloging of instru-
ments can be found in the “168th ENMC International 
Workshop Report”.46 In response to the observed paradox 
between progressive disability and preserved QoL outcomes, 
there is a consensus that there remains a need for develop-
ment of a more sensitive CMT-specific QoL measure.46 The 
recently developed mobility-Disability Severity Index is a 
patient-reported instrument designed by experienced CMT 
practitioners that may offer a complimentary outcome mea-
sure based on patient perspectives.53 A separate large-scale 
INC registry based study used a survey instrument based 
on CMT1A patient input over 20 themes using a six-point 
Likert scale and demonstrated novel themes as prioritized 
by patients and yielded valuable information on symptom 
progression.54 While the use of the aforementioned instru-
ments will continue to evolve, those involved in the optimal 
multidisciplinary care of CMT patients will be required to 
implement and interpret them effectively. Ideally, the afore-
mentioned instruments and outcome measures will eventually 
have generalized utility for the neurologist, genetic counselor, 
physical and occupational therapist, and physiatrist caring 
for the CMT patient.
A large survey of over 400 CMT patients in the INC 
Rare Disease Clinical Research Network Contact registry 
identified patient-reported foot and ankle weakness, balance, 
mobility and hand/finger weakness as the most prevalent 
themes that affected QoL, but also demonstrated that fatigue, 
pain, and body image are likely under-recognized influences 
on perceived QoL.54 Besides function limiting themes such 
as poor balance and mobility limitations, individual symp-
toms reported as most impactful include difficulty/inability 
to run, trouble when getting around slippery surfaces, and 
trouble walking distances and on rough ground. The impact 
of symptoms appear to have the largest effect over the first 
10 years following diagnosis, with a less rapid increase 
over the ensuing years, so that disease progression is bet-
ter predicted by duration than by age. While this may be 
due to survivor bias and improved coping strategies, it also 
argues for more aggressive multidisciplinary supportive 
care over the first decade after diagnosis. The results of 
such studies demonstrate the power of large-scale registry 
and patient-based reporting to identify diverse sets of issues 
important to patients’ QoL that fall outside the realm of a 
single discipline.
Clinical surveillance of 
comorbidities, complications, and 
medications to avoid
Beyond monitoring for and treating physical impairments, 
there is evidence for less well recognized comorbidities and 
complications in CMT. As mentioned earlier, these underap-
preciated problems likely negatively impact QoL, but in many 
cases may be treatable.
Prospective studies regarding the location, severity 
duration, triggering factors, and impact on QoL of cramps 
in CMT demonstrated that hand, finger, thigh, and trunk 
muscle cramps are a stable symptom that clearly impacted 
QoL.40,54 In pediatric CMT1A, muscle cramps, tremor, and 
distal weakness were shown to be associated with lower 
QoL measures.52 Adoption of formerly off-label drugs for 
CMT-related symptoms, such a mexiletine for cramping, 
will likely lead to new indications and improved QoL for 
CMT patients.
Respiratory and sleep disorders observed in CMT include 
restrictive pulmonary impairment, obstructive sleep apnea, 
restless legs syndrome, and vocal cord dysfunction/laryngeal 
neuropathy.55 In a large German web-based survey study 
of over 200 CMT patients, CMT patients reported more 
fatigue, daytime sleepiness, and poorer sleep quality as well 
as a three fold increase in restless leg syndrome.56 A number 
of small reports describe symptoms of dyspnea, dysphagia, 
and obstructive sleep apnea, laryngoscopic evaluation of the 
upper airway, as well as treatment with continuous or bi-level 
positive airway pressure.55,57–62 While there is not enough evi-
dence to make recommendations regarding clinical screening 
for sleep and respiratory disorders, longitudinal care should 
optimally address these potential comorbidities.
Worsening of CMT symptoms during pregnancy has 
been reported.63 This observation has led to investigations 
into progesterone antagonism as a possible therapy in CMT, 
which is discussed in more detail in the “Therapeutics” sec-
tion. CMT was shown to increase the risk for complications 
during delivery, specifically abnormal birth presentation 
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and post partum bleed, and with higher rates of emergency 
interventions during delivery.64 While there are no evidence-
based recommendations regarding obstetric anesthesia, it is 
thought that regional anesthesia is an appropriate alterna-
tive to general anesthesia in CMT patients.65 CMT should 
be considered an independent risk factor for complication 
during pregnancy and delivery and warrants involvement of 
a multidisciplinary team.
Many medications are known to have the potential to 
worsen CMT. The prototypical neurotoxic offenders are che-
motherapies such as taxols and the vinca alkaloids that target 
microtubules.66 These microtubule depolymerizing agents 
are thought to interrupt axonal transport along microtubules 
and worsen preexisting neuropathy or even precipitate new 
neuropathy. This observation has been used to bolster the idea 
that axonal transport explains the length-dependent progres-
sion of CMT.67 Chemotherapies are not the only offending 
agents, and a list of potentially exacerbating medications 
organized by certainty of risk is maintained and updated by 
the CMT Association (http://www.cmtausa.org/).68
Therapeutics
While the last decade has seen the first CMT clinical trials, 
there are no clinical data supporting use of medications, and 
the management of CMT remains supportive. The mainstay 
of supportive care is physical therapy as discussed in the next 
sections. While many drugs are under examination, there is 
only one ongoing clinical trial (PLEO-CMT, ClinicalTrials.
gov identifier NCT02579759) in humans of combination of 
baclofen, naltrexone, and sorbitol (PXT3003).69–71
Clinical trials have been largely driven by observation in 
animal models of CMT1A. The bulk of clinical trial efforts 
centered around the use of ascorbic acid, a known promoter 
of myelination which has been shown to reduce expression 
levels of PMP22, improve locomotor function, and prolong 
life in CMT1A rodent models.72 This led to a randomized 
double-blind, placebo controlled trial of high dose ascorbic 
acid (30 mg/kg/day) in children, with a primary endpoint 
of median nerve motor conduction at 1 year, and secondary 
outcomes of foot and hand strength, motor function, walking 
ability, and QoL.73 A total of 80 children completed the trial, 
and a non significant increase in median nerve conduction 
motor velocity was observed, with no difference in secondary 
outcomes. A similar study in adult CMT1A patients (N=179) 
randomized to 1 g or 3 g of ascorbic acid a day or placebo 
used the CMTNS at 1 year as the primary outcome and 
included secondary outcome measures of muscle strength, 
gait velocity, disability, fatigue, pain, and cramping scales, 
as well as the global impression severity score.74 No sig-
nificant differences in primary or secondary outcomes were 
observed. A third randomized, high dose ascorbic acid (1 g 
twice daily), double-blind study in young adults (age ,25 
years, N=11) using a primary outcome of median NCV and 
neurophysiological secondary outcome measures, failed to 
show any significant effect.75 In these studies, the high doses 
of ascorbic acid treatment were well tolerated. Given the non 
significant results and the slow progression of the disease, it 
was thought that a 1-year follow-up may not have been long 
enough to capture the effect of ascorbic acid. Two subsequent 
2-year trials of low and high doses of ascorbic acid (1.5 g/
day, N=277 and 4 g/day, N=110) in adults failed to show 
significant differences in similar outcome measures.76,77
A number of smaller non randomized non-blinded studies 
have shown potential promise in agents such as coenzyme Q10, 
linoleic acid, and potassium channel blockers, but rigorous 
clinical data are lacking.78,79 The observation that in a small 
cohort of female CMT1 patients (N=21, 45 gestations), 38% 
experienced a worsening of CMT symptoms during pregnancy 
suggests a possible link with pregnancy-associated hormonal 
changes.63 Transgenic rat models of CMT1A implicated pro-
gesterone receptors on Schwann cells as mediating this link to 
progesterone during pregnancy. Administering exogenous pro-
gesterone to CMT1A drove the CMT phenotype, and proges-
terone antagonists reduced PMP22 expression and improved 
CMT phenotypes.80 Further studies demonstrated that anti-
progesterone therapy improved motor strength and axonal 
loss, but did not change myelin thickness or nerve conduction 
velocities, effectively uncoupling axonal loss from demyelina-
tion.81 Formal clinical trials of anti-progesterone therapy in 
CMT have yet to be reported, largely due to the significant 
side effect profile of current anti-progesterones. Additional 
investigations into coenzyme Q10, curcumin, NTF3, and other 
study drugs are at various stages of development.46,82,83
Physical therapy and orthoses
While there are distinct genetic causes, neurophysiological 
properties, and underlying disease mechanisms, the physi-
cal deficits of CMT are uniform enough to approximate and 
discuss it as a singular entity. Future studies of CMT subtypes 
may reveal important differences in response to physical 
therapies, orthotics, and more specific recommendations 
regarding exercise. Likewise, data collection from large 
national patient registries may help investigators retrospec-
tively analyze which durable medical equipment and adaptive 
devices are best suited for improving function in patients with 
CMT along the natural history of the disease.
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Important aspects of physical therapy and rehabilitation 
for patients with CMT may involve gait training, therapeu-
tic exercise, stretching, balance and postural stabilization, 
fall risk prevention strategies, aquatic therapy, energy 
conservation techniques, serial casting/night splinting, 
patient education, training on appropriate assistive devices, 
and prevention of secondary impairments.25–28,84–91 Likewise, 
time should be taken to educate the patient on lifestyle modi-
fications and energy conservation techniques along with the 
progression of the disease and impairments in body structures 
and function.89
Protection of joint range of motion (ROM) to avoid the 
possibility of contractures and maximize functional use of all 
extremities should be stressed in the management of CMT.25 
Night splinting, however, according to the most current 
evidence does not appear to be the most effective means for 
long-term improvements in ankle ROM.28,89 Occupational 
therapy and/or certified hand therapists should be incorpo-
rated with managing both early- and late-stage impairments 
in patients with limited wrist and hand strength and ROM, 
as well as children with hand dysfunction.92 Weakness, pain, 
dysmetria, difficulty with handwriting, and discoordination, 
among several other impairments, may greatly affect upper 
limb function in the patient with CMT as a child or adult and 
they may benefit greatly from occupational, vocational, and 
hand therapies to improve compensatory strategies, utilize 
assistive technology, improve age-appropriate function, and 
accommodate for their impairment.92
Patients with CMT frequently stumble, trip, or fall due 
to weakness and sensory deficits distal to the knee joint, 
and often display compensatory strategies in proximal hip 
and pelvic muscles which are recruited to modify gait pat-
terns.24,90 It has been shown that various types of properly 
fitted ankle–foot orthoses (AFO) may significantly reduce 
the need for proximal compensations and can improve lower 
extremity control during ambulation. Similarly, Dufek et al 
demonstrated that patients with CMT display increased gait 
speed when using AFO compared to no bracing.93 Anterior 
elastic AFO appear to reduce the energy cost of ambulation 
in CMT.94 After fitting of AFO, patients should receive proper 
gait training to assist with adapting and normalizing their bio-
mechanics during locomotion, maximizing their functional 
ambulation potential, and avoiding further compensatory 
movements for energy efficiency.84,93 Likewise, patients 
should be educated on prevention of skin breakdown while 
wearing orthoses and braces.
Orthoses aimed at offering structural support to focal, 
and/or global ankle and foot weakness may range from simple 
shoe inserts to complete AFO bracing, may be plastic or elas-
tic in nature, and may be fabricated from durable plastics to 
custom carbon-fiber composites.24,28,84–91,93,95–97A recent study 
by Wegener et al demonstrated that in a small population 
of adult patients with CMT sensorimotor in-shoe orthoses 
proved to be more comfortable, better cushioned, and had a 
positive effect on overall lower extremity kinematics during 
ambulation.98 A comprehensive evaluation of ROM, sensa-
tion, reflexes, strength, and balance should be performed 
when deciding which AFO device is best suited for each 
individual patient. Despite their effectiveness in improving 
gait, foot pain, and mild balance impairments in patients with 
CMT, adherence to AFO-wearing schedules remains poor.96 
Poor compliance with wearing AFO in CMT has been well 
documented across various age ranges in recent studies, often 
for comfort and cosmetic reasons.99,100
Surgical correction may be required in cases of chronic 
ankle sprains, shoe-wearing difficulty, and pain not helped 
by orthoses.24 Surgical goals are to realign joints, correct 
boney deformities, and to balance muscles, and require a 
high degree of individualization. Evaluation of foot align-
ment, strength, and weight-bearing radiographs are used to 
guide the surgeon’s strategy.
Surgery for foot deformities is common in CMT patients 
yet a systematic review is lacking. Some recent reports have 
suggested early minimally invasive procedures including 
plantar fasciotomy, Achilles tendon lengthening, transfer of 
the peroneus longus to the fifth metatarsal, tendon transfer, and 
hammertoe correction may preserve the utility of braces and 
reduce the need for further surgery.101,102 The aim of an early 
minimally invasive approach is to decrease the forces and intrin-
sic/extrinsic muscle imbalances that underlie progressive foot 
deformity. Later stage reconstructive surgery usually includes 
staged procedures of tendon lengthening and or transfer, osteot-
omy, and arthrodesis.101,102 In the more severe forms of CMT, 
orthopedic correction of spinal deformity and hip dysplasia may 
be required. For a more detailed review of surgical and orthope-
dic issues in CMT, the reader is referred to Yagerman et al.24
Overwork weakness is another common finding through-
out neuromuscular disorders that may require adaptation 
and utilization of energy conservation techniques.89,90 
Although there is conflicting evidence on the concept of 
overwork weakness, recent findings of bilateral hand and leg 
strength suggests it may not manifest in CMT as previously 
thought, and this phenomenon may be more individualized 
to each patient case.90 Therefore, low-to-moderate-intensity 
exercise should be regularly encouraged as it should have 
overall systemic health benefits.25,26,90,103 Interval training, 
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by its very nature incorporating periods of rest and exercise, 
appears to display marked improvements in cardiorespira-
tory, strength, and functional capacities, and likely slows or 
reverses the deconditioning process often seen in patients 
with CMT.26,104,105
Low-intensity exercise appears to be more beneficial 
for patients with neuromuscular disease when compared to 
high- resistance or high-intensity exercise.25Aquatic therapy, 
in theory, may be of great benefit due to its unweighting 
properties and dynamic resistance during underwater move-
ments, but more evidence and studies are needed in this area. 
Likewise, a home-based resistance training exercise program 
focused on activities of daily living (ADL)-specific exercises 
improved strength and ADL equally in both adult males and 
females with CMT.105 Stretching should play an important 
role in the maintenance of patients with CMT to protect 
joint ROM in order to optimize the functional use of their 
extremities as their weakness persists. Occupational therapy 
should also be considered for those patients needing adaptive 
equipment and further training to improve independence with 
self-care and ADL.
Patients with CMT will commonly present with increas-
ing sensorimotor loss distal to the knee that will greatly 
benefit from AFO and the ongoing care of an orthotist. Also, 
interval training, and low- to-moderate-intensity aerobic and 
resistance exercise can be therapeutic and is not likely to 
negatively impact a patient’s function. Energy conservation 
techniques and lifestyle modifications are key educational 
concepts for the patient with CMT, albeit, are very patient-
specific. Often patients with CMT will develop weakness and 
limited ROM in their wrists and hands in later stages that 
can be addressed by skilled hand therapists, and occupational 
and physical therapy modalities. Patients with CMT should 
invariably be part of an ongoing multidisciplinary plan of 
care in regards to their functional impairments; including 
but not limited to: physical and occupational therapist, phy-
siatrist, orthotist, neurologist, and hand therapist, in order to 
manage each impairment to its fullest and achieve maximum 
functional benefit. More high-quality trials and evidence are 
needed to draw sound conclusions on the benefits of aquatic 
therapy, specific therapeutic modalities, exercising, stretch-
ing protocols, balance training, night splinting/serial casting, 
and assistive technology devices in the management of CMT 
disease. Likewise, the emergence of large-scale patient reg-
istries, such as the INC and well-defined natural histories, 
will enable researchers to investigate how therapies might 
be optimally tailored to the needs of specific CMT clinical 
and genetic subtypes.
The need for multidisciplinary  
care in CMT
In summary, while the medical diagnosis of CMT is tra-
ditionally made by the neurological specialist, the optimal 
management of CMT patients includes genetic counselors, 
physical and occupational therapists, physiatrists, orthotists, 
social workers, mental health providers, and community 
resources (Table 2). Continued genetic discoveries continue 
to add to the complexity of CMT, and knowledge of each 
CMT subtype will likely shape the way each member of 
the multidisciplinary team approaches the disease. Sev-
eral important trends in CMT research discussed earlier, 
including the development of large multicenter patient reg-
istries, standardized clinical instruments to assess disease 
progression and disability, and increasing recognition of 
patient-reported factors will likely make significant improve-
ments to CMT patients’ QoL. These developments have 
and will continue to identify novel targetable and treatable 
Table 2 Multidisciplinary members and roles in the diagnosis and 
management of CMT
Neurologist •  evaluation and diagnosis
•  Prognostication
•  Consideration for research studies
•  Referrals to genetic counselors, PT/OT, 
mental health
•  Longitudinal care and reevaluation
•  Counseling on medications to avoid
•  Surveillance of comorbidities
•   Lifestyle modifications to limit disability
Genetic counselor and  
social worker
•  Guidance in clinical- and research-based 
genetic testing
•  ensuring ADA and GiNA compliance
•  Discussion of family testing
•  Reproductive counseling
•  Referral to CMT Association and other 
community organization
Physical and occupational 
therapist/physiatrist
•  evaluation of upper and lower 
extremity disability
•  Prescription for ankle–foot orthotics
•  Recommendations for therapeutic 
exercise, stretching, balance and 
postural stabilization, fall risk 
prevention strategies
•  Recommendation on exercise, lifestyle 
modification to limit disability
Psychologist/psychiatrist •  evaluation and treatment of anxiety, 
depression, and other psychosocial 
impact of diagnosis, such as body image
Orthopedic surgeon •  evaluation and treatment of severe 
foot, ankle, hip, and spine deformities
Abbreviations: CMT, Charcot–Marie–Tooth; ADA, Americans with Disabilities 
Act; GiNA, Genetic information Nondiscrimination Act of 2008; PT, physical 
therapist; OT, occupational therapist.
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deficits, symptoms, and disabilities that will likely require a 
collaborative multidisciplinary approach (Figure 1). Many of 
these multidisciplinary services are coordinated and offered 
by muscular dystrophy clinics or established CMT-based 
clinics (Charcot–Marie–Tooth Disease Clinic at the Univer-
sity of Iowa (https://www.uihealthcare.org/charcot-marie-
tooth-disease/). Ongoing CMT research struggles to identify 
novel therapeutics to slow or stop disease progression, but 
the evolving strategies in long-term multidisciplinary care of 
CMT patients is critical in maintaining QoL and functional-
ity with disease progression.
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